Martin Dow has received an establishment licence from the Drug Regulatory Authority of Pakistan (DRAP) for re-filling and labelling of its new clinical chemistry reagents down-filling facility.

This marks an important milestone in advancing import substitution in Pakistan’s diagnostics sector.

With Martin Dow’s new clinical chemistry reagents down-filling facility Martin Dow continues to build on a legacy of delivering high-quality diagnostic reagents locally, strengthening accessibility for laboratories nationwide while driving progress towards the national goal of strengthening local production.

Developed with an investment of approximately Rs. 50 million, the project spans 2,600 square feet and is designed with a production capacity of over 6 million packs annually. It is the first of its scale facility in Pakistan, purpose-built to meet both current and future diagnostic needs. The facility has been designed to meet global standards of efficiency, safety, and compliance administered by DRAP, ensuring hygiene, operational excellence, and reliability at every stage of production.

Commenting on this milestone, Dr. Suleman Alvi, Country Head of Martin Dow Specialities Pvt Ltd, said, “The DRAP approval of our new clinical chemistry reagents down-filling facility is a landmark for Martin Dow and for Pakistan’s healthcare sector. It moves us closer to reducing reliance on imported diagnostic reagents while making diagnostics solutions more affordable and accessible. At Martin Dow Specialities, we are committed to strengthening local capabilities and supporting better healthcare outcomes through innovation and self-reliance.”

Martin Dow Specialities is a leading a company in Pakistan with an approved facility for clinical chemistry reagents down-filling, these clinical chemistry reagents are the-in-vitro diagnostics (IVD), ready-to-use, liquid reagents for quantitative determination of pathological tests in open-system clinical chemistry analyzers.